Condition 1: Autologous stem cell transplantation. Condition 2: SARS-CoV-2 vaccine efficacy. SARS-CoV-2 vaccine effectiveness
Conditions
Interventions
Intervention 1: Intervention group: All patients who underwent autologous SCT and have inclusion criteria will be enrolled and will receive the first dose of pastocovac from 3 months post-transplant.
Sponsors
Tehran University of Medical Sciences
Pasture Institute of Iran
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: ?All autologous stem cell transplantation Age >=18
Exclusion criteria
Exclusion criteria: patients who received Rituximab during the past six months. Patients who do not consent to vaccination after transplantation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 specific IgG (anti-S1) titer. Timepoint: Four weeks after the second vaccine. Method of measurement: Enzyme-linked immunosorbent assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 specific IgG (anti-S1) titer. Timepoint: Four weeks after the first vaccine. Method of measurement: ?Enzyme-linked immunosorbent assay.;Cumulative incidence of COVID-19. Timepoint: 12 months following bone marrow transplantation. Method of measurement: RT-PCR test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeyla Sharifi Aliabadi
Tehran University of Medical Sciences
Outcome results
None listed